ArticleProteins2026
In Silico Structural Analysis of Human β-Glucuronidase for Antibody-Drug Conjugates Optimization.
Article in Proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human β-glucuronidase (HGUSB), a key lysosomal glycosyl hydrolase for the degradation pathway of glycosaminoglycans (GAGs), plays a crucial role in cell proliferation and inflammation, making it a promising target for novel therapeutic strategies including antibody-drug conjugates (ADCs) with β-glucuronic linkers. In this study, molecular docking and molecular dynamics (MD) simulations were performed to investigate the conformational stability of HGUSB in complex with different ligands, including substrates, inhibitors, and β-glucuronic linkers. Our rationale approach includes the evaluation of commercial substrates and a known inhibitor with different binding stoichiometries to identify the most favorable configuration and the most stable conformation of the enzyme. Based on the binding mechanism of HGUSB to these well-known ligands, the interaction with commercial linkers was evaluated, providing a structural determination of the recognition mechanism between the enzyme and ADCs. MD simulations on HGUSB::Linker complexes revealed that the maleimide-containing hydrophilic β-glucuronide, exhibited the most stable binding making it the best fitting linker among those analyzed in this study. Overall, this study identifies the optimal binding configuration of the HGUSB enzyme for investigating small molecule interactions and, despite the endogenous homotetrameric assembly, justifies the use of a simplified monomeric model for the study of larger macromolecular complexes, like linker analysis, ensuring an efficient and accurate computational approach. These findings lay the groundwork for a rationale optimization of β-glucuronic linker-based ADCs, offering new perspectives for targeted cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.